CB
CBIO.US Crescent Biopharma, Inc.
- Market cap
- USD 526M
- P/E
- -
- P/B
- 3.36x
- ROE
- -40.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CBIO.US undervalued?
Graham numberThe Graham number of Crescent Biopharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Crescent Biopharma, Inc. fundamental analysis
No fundamental analysis for Crescent Biopharma, Inc. yet.
Crescent Biopharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly k…
Full company profileCrescent Biopharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Crescent Biopharma, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.5K | - | - | - | 10.2M | 1.16M | 75.0K | 10.0K | - | 10.8M | 5.54M |
| Gross Profit | 18.5K | -264K | -275K | -899K | 10.2M | 1.16M | 75.0K | 10.0K | -35.2K | 10.8M | - |
| Operating Income | -31.9M | -33.9M | -51.5M | -61.4M | -51.5M | -63.4M | -47.4M | -39.3M | -49.9M | -153M | -121M |
| EBITDA | -31.7M | -33.7M | -51.2M | -57.0M | -51.2M | -63.2M | -47.2M | -39.1M | -44.2M | -150M | -117M |
| Net Income | -31.8M | -33.3M | -48.3M | -54.1M | -51.0M | -63.4M | -46.7M | -36.9M | -48.5M | -154M | -112M |
| EPS | -150 | -113 | -118 | -125 | -112 | -123 | -89 | -58 | -63 | -15 | -2.86 |
| Balance Sheet | |||||||||||
| Total Assets | 42.4M | 129M | 215M | 168M | 143M | 94.3M | 51.8M | 45.3M | 35.6M | 240M | 300M |
| Total Liabilities | 7.09M | 8.88M | 9.38M | 13.8M | 14.6M | 12.7M | 8.88M | 6.90M | 51.1M | 37.3M | 25.2M |
| Shareholders' Equity | 35.3M | 120M | 205M | 154M | 128M | 81.6M | 42.9M | 38.4M | -15.5M | 203M | 274M |
| Cash & Short-term Investments | 40.0M | 124M | 210M | 158M | 137M | 90.3M | 47.9M | 41.8M | 34.8M | 213M | 289M |
| Total Debt | - | - | - | 3.62M | 2.82M | 1.92M | 919K | 808K | 37.5M | 1.64M | 2.46M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.7M | -29.8M | -43.3M | -52.0M | -39.2M | -57.5M | -46.5M | -34.9M | -31.1M | -71.5M | -73.8M |
| Capital Expenditure | 704K | 294K | 126K | 145K | 68.5K | 14.9K | 84.2K | 21.4K | 9.97K | 72.9M | 10.9M |
| Free Cash Flow | -30.4M | -30.1M | -43.5M | -52.1M | -39.3M | -57.5M | -46.5M | -34.9M | -31.1M | -144M | -84.7M |
| Ratios | |||||||||||
| ROE | -90.1% | -27.8% | -23.5% | -35.1% | -39.8% | -77.7% | -108.8% | -96.1% | - | -75.8% | -40.7% |
| ROA | -75.0% | -25.9% | -22.5% | -32.2% | -35.7% | -67.2% | -90.1% | -81.4% | -136.2% | -64.1% | -37.3% |
| Net Profit Margin | -171,945.1% | - | - | - | -502.1% | -5,469.0% | -62,251.7% | -368,994.2% | - | -1,419.6% | -2,013.9% |
| Debt to Equity | - | - | - | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | - | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Crescent Biopharma, Inc. dividends
Crescent Biopharma, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jun 16, 2025.
Who owns Crescent Biopharma, Inc.
- Insiders 0.27%
- Institutions 91.30%
- Public & others 8.43%
- Shares outstanding 37.1M
- Free float 24.6M
Top funds holding CBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Small Cap Growth | 960K | 2.58% | +0.93% | Aug 2026 |
| Fidelity Growth Company Fund | 939K | 2.53% | +221.28% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 907K | 2.44% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 718K | 1.93% | 0.00% | Oct 2026 |
| Fidelity Small Cap Growth K6 | 466K | 1.25% | +1.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 457K | 1.23% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 357K | 0.96% | +2.69% | Oct 2026 |
| Fidelity Select Biotechnology | 340K | 0.91% | +78.32% | Aug 2026 |
| PGIM Jennison Health Sciences Z | 311K | 0.84% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 308K | 0.83% | +2.12% | Aug 2026 |
| Fidelity Growth Company K6 | 290K | 0.78% | +179.79% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 272K | 0.73% | -0.38% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 244K | 0.66% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 240K | 0.65% | +1.57% | Aug 2026 |
| Fidelity Series Growth Company | 234K | 0.63% | +238.75% | Aug 2026 |
| Vanguard Russell 2000 ETF | 169K | 0.45% | +36.35% | Sep 2026 |
| Fidelity Advisor Health Care I | 153K | 0.41% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 138K | 0.37% | +259.48% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 89.2K | 0.24% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 88.1K | 0.24% | 0.00% | Oct 2026 |
Top institutions holding CBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 4.13M | 11.13% | 0.00% | Jun 2026 |
| Bvf Inc | 2.75M | 7.40% | 0.00% | Jun 2026 |
| Fairmount Funds Management LLC | 2.75M | 7.40% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 2.13M | 5.74% | 0.00% | Jun 2026 |
| Logos Global Management LP | 1.90M | 5.11% | +293.78% | Jun 2026 |
| FCPM III SERVICES BV | 1.68M | 4.52% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 1.66M | 4.48% | +10.12% | Jun 2026 |
| Vestal Point Capital LP | 1.63M | 4.39% | +8.67% | Jun 2026 |
| Opaleye Management Inc | 1.32M | 3.55% | +0.51% | Jun 2026 |
| BlackRock Inc | 1.27M | 3.42% | +998.95% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.16M | 3.12% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 768K | 2.07% | -4.20% | Jun 2026 |
| Boxer Capital Management, LLC | 454K | 1.22% | 0.00% | Jun 2026 |
| Millennium Management LLC | 404K | 1.09% | +24.82% | Jun 2026 |
| Geode Capital Management, LLC | 385K | 1.04% | +269.00% | Jun 2026 |
| Jennison Associates LLC | 379K | 1.02% | +147.43% | Jun 2026 |
| NEXTBio Capital Management LP | 373K | 1.00% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 373K | 1.00% | 0.00% | Jun 2026 |
| Remedium Capital Partners, LLC | 361K | 0.97% | 0.00% | Jun 2026 |
| State Street Corp | 316K | 0.85% | +707.81% | Jun 2026 |
Crescent Biopharma, Inc. company profile
- Company name
- Crescent Biopharma, Inc.
- Ticker
- CBIO.US
- ISIN
- KYG2545C1042
- Exchange
- USA Stocks
- Listed since
- Jan 10, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 300 Fifth Avenue, Waltham, MA, United States, 02451
- Phone
- 617 430 5595
- Website
- crescentbiopharma.com
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc. management
10- Mr. Joshua T. BrummCEO & Director · born 1978
- Dr. Jonathan McNeill M.D.President & COO · born 1985
- Dr. Ellie Im M.D.Chief Medical Officer · born 1978
- Mr. Richard William Scalzo M.B.A.Chief Financial Officer · born 1986
- Mr. Ryan LynchSenior VP of Finance, Treasurer & Chief Accounting Officer · born 1984
- Dr. Wenjie Cheng Ph.D.Senior Vice President of Technical Operations
- Dr. Jan Pinkas Ph.D.Chief Scientific Officer · born 1969
- Ms. Barbara Bispham Hale J.D.General Counsel & Corporate Secretary · born 1987
- Ms. Amy ReillyChief Communications Officer · born 1974
- Mr. Christopher DoughtyChief Business Officer · born 1988